The objective of drug targeting is to deliver drugs to a specific site of action through a carrier System. Monoclonal antibody (MAb) has proved itself as a magic bullet against many dangerous diseases like cancer (breast cancer, lung cancer, colorectal cancer, ovarian cancer, colon cancer, etc), cardiovascular diseases, bone marrow and organ transplant rejection, Crohn’s disease, Graft-versus-host disease, leukemia and many more diseases. In cancer chemotherapy, cytotoxic drugs kill cancerous cells but also damage normal cells. MAb generated against specific antigens, when conjugated to cytotoxic drugs, can selectively deliver drugs to cancer cells while minimizing damage to normal cells. Of all the carrier systems available, MAb are gaining importance because of their high specificity. MAb has application in many fields such as diagnostic, therapeutic, chemotherapeutic, investigational and analytical. The therapeutic applications of MAb are broadened by combining it with cytotoxic agents. The spectrum of MAb is increasing day by day. It is like “Monoclonal Antibodies” are following the human imagination. In the coming era MAb may open the new areas of clinical research against the life threatening disease like AIDS and cancer. The purpose of this review is to provide a comprehensive account of the use of MAb in drug targeting, highlighting their scope and limitations.
Loading....